Détails du projet
Objectif du projet
P-PEAKS is a multicenter, intercontinental Phase II randomized controlled trial evaluating the safety, efficacy, and feasibility of personalized bacteriophage therapy in combination with intravenous beta-lactam antibiotics for the secondary prevention of recurrent urinary tract infections (rUTIs) caused by Escherichia coli in female patients. The project aims to deliver an improved, effective and meaningful solution for the prevention of recurrent UTIs in female patients improving their health outcomes and quality of life.
Role de l'organisme
Partner beneficiary in charge of the phage production and testing.
Sources de financement
This project is co-financed by the Horizon Europe program (Grant number: 101289070).
| Titre abrégé | Personalized-Phage Against E. Coli with IV Antibiotic to Knockout Stable Biofilms in Urinary Tract Infections |
|---|---|
| L'acronyme | P-PEAKS UTI |
| statut | Non commencé |
| Les dates de début/date réelle | 1/06/26 → 31/05/30 |
Partenaires de collaboration
- École royale militaire
- Unity Health Toronto (lead)
- TARTU ULIKOOL
- HADASSAH MEDICAL ORGANIZATION
- Assistance Publique-Hôpitaux de Paris Centre Université-Paris
- FUNDACION PUBLICA GALEGA DE INVESTIGACION BIOMEDICA INIBIC
- The Hebrew University of Jerusalem
- University College London
- Lund University
- University of Calgary
- UNIVERSITE LAVAL
- Europaischer Nierenpatientenverband
- AZIENDA OSPEDALIERO UNIVERSITARIA PISANA
- Mayo Clinic
- FAGOTERAPIA LAB S.R.L.
- SIHTASUTUS TARTU ULIKOOLI KLIINIKUM
- BAYLOR COLLEGE OF MEDICINE
- PHILIPPS UNIVERSITAET MARBURG
- MICRON RESEARCH LIMITED
- THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
- QEEN BIOTECHNOLOGIES INC.
Empreinte digitale
Explorez les thèmes de recherche abordés par ce projet. Ces libellés sont générés sur la base des prix/subventions sous-jacents. Ensemble, ils forment une empreinte digitale unique.